All In Biotech

Drug Trial Radar · NCT07644039

Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies

A Multicenter, Open-label, Phase 1/2 Safety Run-in and Expansion Study of PM54 in Combination With Immunotherapy Evaluating Safety and Efficacy in Adult Participants Who Were Previously Treated for Advanced Malignancies

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

119

Planned (sponsor's estimate)

Start

May 21, 2026

Primary completion

Apr 2, 2029

Study completion Apr 2, 2029

Sponsor

Lead sponsor
PharmaMarIndustry
Sponsor type
Industry
First posted
Jun 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of the study is to evaluate the safety, tolerability and recommended dose of PM54 in combination with pembrolizumab. To assess the antitumor activity of PM54 in combination with pembrolizumab in terms of clinical benefit rate (CBR) and objective response rate (ORR) based on investigator's assessment in participants in other cohorts.

Conditions

  • Advanced Malignancies

Interventions

  • PembrolizumabDrug

    Intravenous infusion.

  • PM54Drug

    Intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts 1 and 2: Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Treatment DiscontinuationTime frame: From signing of the informed consent up to 30 days after last dose (up to 3 years)
  2. Part 1: Number of Participants with Dose-Limiting Toxicities (DLTs)Time frame: Cycle 1 (each cycle is of 21 days)
  3. Part 2: Clinical Benefit RateTime frame: up to 12 weeks
  4. Part 2: Objective Response RateTime frame: Baseline up to 3 years

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • START New York

    New York, New York · Recruiting

  • START Dallas

    Fort Worth, Texas · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Houston

    Houston, Texas · Recruiting

  • NEXT Dallas

    Irving, Texas · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • Institut Català d'Oncologia (ICO) - Hospital Durans i Reynals.

    Barcelona, Spain · Recruiting

  • Clinica Universidad de Navarra (CUN)

    Madrid, Spain · Recruiting

  • Hospital General Universitario Gregorio Marañón

    Madrid, Spain · Recruiting

  • START Madrid - Hospital Universitario Fundacion Jimenez D

    Madrid, Spain · Recruiting

  • Clinica Universidad de Navarra (CUN)

    Pamplona, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.